FDA Approved: TYSABRI — Supplemental Application (Biogen Inc.)

View source ↗

Summary

The FDA approved Biogen's supplemental application for TYSABRI (natalizumab), resulting in a labeling update as part of a supplemental approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

SUPPL AP for TYSABRI (NATALIZUMAB)